MacGrath and Koleske have provided an excellent review of cortactin as a promising target molecule in cancer therapy approaches [10], showing the importance of clarifying the role of cortactin in PDAC progression as well as of identifying and understanding its interactions with other proteins that contribute to cancer migration and invasion in an effort to combine various strategies in multimodal therapy approaches and thereby prolong recurrence-free survival of PDAC patients. Here, CTTN is linked to cancer.